登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：300009 证券简称：安科生物 公告编号：2025-042 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到证监会指定媒体仔细阅读半年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 □适用 √不适用 公司计划不派发现金红利，不送红股，不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ 持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况 □适用 √不适用 前10名股东及前10名无限售流通股股东因转融通出借/归还原因导致较上期发生变化 □适用 √不适用 公司是否具有表决权差异安排 □是 √否 二、公司基本情况 1、公司简介 ■ 2、主要会计数据和财务指标 ■ 3、公司股东数量及持股情况 单位：股 4、控股股东或实际控制人变更情况 控股股东报告期内变更 □适用 √不适用 ...

Core Viewpoint - The report highlights the financial performance and strategic positioning of Anhui Anke Biotechnology Group Co., Ltd. during the first half of 2025, emphasizing the company's focus on innovation in the biopharmaceutical sector and its response to market demands and regulatory changes [1][3]. Financial Performance - The company reported a revenue of approximately 1.29 billion yuan, a decrease of 0.51% compared to the previous year [2][16]. - The net profit attributable to shareholders was approximately 366.5 million yuan, reflecting a decline of 11.92% year-on-year [2][16]. - The basic earnings per share decreased by 11.72% to 0.2191 yuan [2][16]. - Total assets at the end of the reporting period were approximately 4.92 billion yuan, down 4.14% from the previous year [2][16]. Industry Overview - The biopharmaceutical industry is recognized as a strategic emerging industry in China, with significant growth potential driven by technological advancements and an aging population [3][4]. - The global biopharmaceutical market is projected to reach 1.71 trillion USD by 2025, with China leading the growth at a compound annual growth rate (CAGR) of 14.5% [3][4]. - The industry is undergoing a transformation towards precision, intelligence, and innovation, supported by favorable government policies [3][4]. Company Positioning - The company is positioned as a national high-tech enterprise with strong independent innovation capabilities, having undertaken numerous national and provincial projects [3][4]. - It has achieved significant milestones, including the commercialization of the first domestic human interferon α2b and the launch of various innovative drugs [3][4]. - The company is actively expanding its product pipeline, focusing on monoclonal antibodies, bispecific antibodies, and innovative ADC drugs [3][4]. Business Segments - The main business includes the research, development, production, and sales of biopharmaceuticals, with a focus on gene-engineered drugs and biological diagnostic reagents [5][6]. - The company has successfully launched new products, such as the Acetate Atosiban injection, enhancing its competitive position in the assisted reproductive medicine market [5][6]. - The product portfolio includes human interferon α2b, human growth hormone, and various traditional Chinese medicine products, catering to a wide range of medical needs [5][6]. Strategic Initiatives - The company is committed to enhancing its core competitiveness by accelerating the R&D and commercialization of innovative drugs [5][6]. - It aims to strengthen collaborations with domestic and international research institutions and enterprises to drive technological innovation [5][6]. - The company is focused on optimizing its business structure and expanding market channels to improve operational efficiency and overall business growth [5][6].

末增减 持股 5%以上股东、前 10 名股东及前 10 名无限售流通股股东参与转融通业务出借股份情况 □适用 ?不适用 前 10 名股东及前 10 名无限售流通股股东因转融通出借/归还原因导致较上期发生变化 □适用 ?不适用 公司是否具有表决权差异安排 □是 ?否 控股股东报告期内变更 □适用 ?不适用 公司报告期控股股东未发生变更。 实际控制人报告期内变更 □适用 ?不适用 公司报告期实际控制人未发生变更。 | 2025 安徽安科生物工程(集团)股份有限公司 年半年度报告摘要 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 安徽安科生物工程(集团)股份有限公司 | | 2025 | 年半年度报告摘要 | | | | | 证券代码：300009 | 证券简称：安科生物 | 公告编号：2025-042 | | | | | | 安徽安科生物工程(集团)股份有限公司 | | | | | | | | 安徽安科生物工程(集团)股份有限公司 | | | | 2025 | 年半年度报告摘 | | | 要 | | | | | | | | 一、重要提示 | ...

2025年7月21日，宜品娟姗奶粉新品发布会暨宜品与叶义言医疗签约合作仪式在湖南长沙圆满举行。宜 品乳业集团副董事长兼爱尼可总经理刘国民，宜品爱尼可全国市场总监欧林松；湖南叶义言医疗董事长 叶韬，湖南叶义言医疗研发中心主任周蓉；长沙宜品总经理陈宏兵，长沙驱驰电商总经理黄婧，长沙宜 品项目负责人肖正勇等领导嘉宾出席了活动，一同见证宜品娟姗奶粉新品启幕的高光时刻。 本次发布的6款儿童成长奶粉和学生奶粉均为100%娟姗奶源，为3岁+儿童青少年带来长高营养新选择。 同时，这也进一步完善了宜品儿童学生奶粉的产品线，拓展了高端娟姗产品领域，在品牌发展中开辟了 新的增长点。 在本轮发布的6大新品当中，初乳碱性蛋白CBP、赖氨酸、水解蛋黄粉、维生素D、高钙，为3~14岁儿 童青少年的骨骼成长提供支持；3重活性益生菌+3重益生元+优量乳铁蛋白等内护群珍稀营养；磷脂酰 丝氨酸、DHA+ARA、SA等成分，为学龄阶段孩子提供脑视营养支持。 产品覆盖3岁+儿童青少年成长发育关键期所需要的骨骼、眼脑、自护、吸收等多个维度的全面营养支 持。 宜品x叶义言医疗携手儿童生长发育领域共进共促 100%珍稀娟姗奶源天然纯净守护天生金贵 宜品儿童 ...